Learning from history: How government price setting and other anti-innovation policies negatively impact biopharmaceutical R & D

Today, America leads the world in medical innovation because of our unique research ecosystem, but that wasn ’t always the case. Anew paper from NDP Analytics, “Will US Leadership in Biopharmaceutical R&D Continue? Consequences of Price Controls and Other Anti-Innovation Policies, ” takes a look at the positive and negative impacts that public policies can have on biopharmaceutical innovation – namely how the adoption of government price setting and other anti-innovation policies across Europe in the 1980s and 1990s pushed the locus of R&D investment away from the continent to countries with more pro-innovation policies, principally the United States.
Source: The Catalyst - Category: Pharmaceuticals Tags: Research and Development International Reference Pricing Source Type: news